ChemicalBook > CAS DataBase List > CSF1R-IN-2

CSF1R-IN-2

Product Name
CSF1R-IN-2
CAS No.
2271119-26-5
Chemical Name
CSF1R-IN-2
Synonyms
TPX-0022;CSF1R-IN-2;Elzovantinib;CSF1R inhibitor 2;TPX-0022(CSF1R-IN-2);Elzovantinib (TPX-0022);CSF1R-IN-2, 10 mM in DMSO;Elzovantinib (TPX-0022) ，S9620;Elzovantinib (TPX-0022, CSF1R-IN-2);colony stimulating factor 1 receptor,CSF-1R,CSF1R IN 2,inhibit,CSF1RIN2,c-Met/HGFR,CSF1R,CSF-1R-IN-2,Inhibitor,CSF-1 receptor,Src,c-Fms
CBNumber
CB95848846
Molecular Formula
C20H20FN7O2
Formula Weight
409.42
MOL File
2271119-26-5.mol
More
Less

CSF1R-IN-2 Property

storage temp. 
Store at -20°C
solubility 
DMSO : 25 mg/mL (61.06 mM; Need ultrasonic)
form 
A solid
color 
White to off-white
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

N-Bromosuccinimide Price

ChemScene
Product number
CS-0091874
Product name
CSF1R-IN-2
Purity
99.97%
Packaging
5mg
Price
$350
Updated
2021/12/16
ChemScene
Product number
CS-0091874
Product name
CSF1R-IN-2
Purity
99.97%
Packaging
10mg
Price
$550
Updated
2021/12/16
ChemScene
Product number
CS-0091874
Product name
CSF1R-IN-2
Purity
99.97%
Packaging
50mg
Price
$1650
Updated
2021/12/16
More
Less

CSF1R-IN-2 Chemical Properties,Usage,Production

Uses

Elzovantinib (TPX-0022) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively[1].

in vivo

Elzovantinib (TPX-0022; p.o., BID, 13 days) treatment results in an 85% tumor regression and no body weight loss is observed after 21 days treatment in mice[1].
Elzovantinib (p.o., BID, 10 days) demonstrates the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively in SCID/Beige mice[1].
Elzovantinib inhibits MET activity in MKN-45 tumors following oral administration in mice[1].

Animal Model:Mice bearing LU2503 tumors patient derived xenograft (PDX) NSCLC model[1].
Dosage:15 mg/kg.
Administration:PO, BID (twice daily) for 13 days.
Result:Resulted in an 85% tumor regression and no body weight loss was observed after 21 days treatment.
Animal Model:SCID/Beige mice bearing Ba/F3 ETV6-CSF1R tumors with average tumor size of ~180 mm3[1].
Dosage:5 and 15 mg/kg.
Administration:PO, BID (twice daily) for 10 days.
Result:Demonstrated the ability to inhibit tumor growth at 44% and 67% at the dose of 5 mg/kg, BID and 15 mg/kg, BID, respectively.

References

[1] WO 2019023417 A1.

CSF1R-IN-2 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

CSF1R-IN-2 Suppliers

China 41 United States 3 Global 44
TargetMol Chemicals Inc.
Tel
+1-781-999-5354; +17819995354
Email
marketing@targetmol.com
Country
United States
ProdList
32435
Advantage
58
TargetMol Chemicals Inc.
Tel
+1-781-999-5354;
Email
support@targetmol.com
Country
United States
ProdList
39035
Advantage
58
Cayman Chemical Company
Tel
--
Fax
--
Email
cayman@caymanchem.com
Country
United States
ProdList
6213
Advantage
81

2271119-26-5, CSF1R-IN-2Related Search:

Repotrectinib TPX-0131 17,19-Metheno-1H,5H-cyclopent[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, 7-fluoro-2,3,3a,12,13,20a-hexahydro-11-methyl-, (3aS,11R,20aR)- TPX-0046

  • CSF1R-IN-2
  • CSF1R inhibitor 2
  • 1,15-Etheno-1H-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecine-12-carbonitrile, 3-amino-14-ethyl-11-fluoro-4,5,6,7,13,14-hexahydro-7-methyl-4-oxo-, (7S)-
  • TPX-0022
  • TPX-0022(CSF1R-IN-2)
  • Elzovantinib (TPX-0022)
  • colony stimulating factor 1 receptor,CSF-1R,CSF1R IN 2,inhibit,CSF1RIN2,c-Met/HGFR,CSF1R,CSF-1R-IN-2,Inhibitor,CSF-1 receptor,Src,c-Fms
  • Elzovantinib
  • (S)-12-Amino-2-ethyl-45-fluoro-6-methyl-9-oxo-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenacyclononaphane-46-carbonitrile
  • CSF1R-IN-2, 10 mM in DMSO
  • Elzovantinib (TPX-0022, CSF1R-IN-2)
  • Elzovantinib (TPX-0022) ，S9620
  • 2271119-26-5